School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Kardigan, Inc. KARD

Healthcare · Biotechnology

$14.67last close 2026-10-09 · market cap $1.37B · delayed data

Trailing returns

1M-25.46%
3M-40.00%

Basis: Adjusted daily closes.

What it does

Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure.

Open KARD in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies